AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04419792 — intervention group
Intervention type: OTHER
Intervention: Assessment of physical performance variables
Description: Other:~Assessment of physical performance indices using the following outcome measures:~Cardiopulmonary fitness: YMCA submaximal bike test Upper Body: ACSM press up test, Dynamometry Lower body: Wall squat test, Countermovement jump test
Study NCT04549753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current simulation
Description: Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
Study NCT03480386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Pulmonary Rehabilitation
Description: Twice daily exercise routine six days a week of 3 minutes of personal breathing, 5 exercises with 10 reps each, and 6 minutes of walking with weekly health coach calls.
Study NCT04186923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: F-SPOKE
Description: This project includes communicative, emotional, and also organizational support with outreach across different sectors and phases (F-SPOKE - family-centered, cross-sector and cross-phase organizational, communicative, and emotional support).
Study NCT00776334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril 40mg Tablets
Study NCT00776334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril 40mg Tablets
Study NCT02979028 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TEAS
Description: Transcutaneous electrical acupoint stimulation
Study NCT02979028 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS
Description: Transcutaneous electrical acupoint stimulation
Study NCT02979028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Transcutaneous electrical acupoint stimulation
Study NCT04328441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
Study NCT04328441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracutaneously 0.1ml NaCl 0,9%
Study NCT01007513 — intervention group
Intervention type: PROCEDURE
Intervention: Transvaginal ultrasound
Description: A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
Study NCT01007513 — intervention group
Intervention type: PROCEDURE
Intervention: Vaginal secretion sampling
Description: Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
Study NCT04430790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxapram
Description: Loading dose and continuous doxapram infusion.
Study NCT04430790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Loading dose and continuous placebo infusion.
Study NCT00049504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00049504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00049504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or orally
Study NCT00049504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given orally
Study NCT00049504 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT00049504 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies
Study NCT00049504 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study NCT00049504 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT00049504 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation
Study NCT00049504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo haploidentical hematopoietic bone marrow transplantation
Study NCT00049504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo haploidentical hematopoietic bone marrow transplantation
Study NCT02575300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
Study NCT03431792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Tail Balloon
Description: s. description of experimental Arm
Study NCT01522768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib and Paclitaxel
Description: All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m\^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
Study NCT04523467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-angiogenic Targeted Drugs
Description: A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma
Study NCT04523467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginsenoside Rg3
Description: An active ingredient extracted from ginseng leachate, which can restrain angiogenesis and reduce the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface and block the binding of programmed cell death 1 (PD-1) and PD-L1
Study NCT04523467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer
Study NCT04523467 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer
Study NCT04732572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep and healthy lifestyle education
Description: Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.
Study NCT04732572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and healthy lifestyle education
Description: Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.
Study NCT04732572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other supportive care
Description: Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.
Study NCT04732572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other supportive care
Description: Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.
Study NCT04732572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Description: Surgery will be performed by board-certified otolaryngologists with or without the assistance of resident physicians in accredited otolaryngology training programs. Prior to the surgical procedure, tonsillar size will be graded using a standardized scale of 0-4. Extent of adenoid tissue will also be graded as mild (0-33%), moderate (34-66%) or severely (67-100%) obstructing the posterior choanae. Complete bilateral tonsillectomy and removal of obstructing adenoid tissue will be performed by cold dissection, monopolar electrocautery or plasma knife-assisted surgical technique under general anesthesia. All procedures will be performed using inpatient facility for 3-4 days.
Study NCT00615459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 μg or 300 μg, delivered via SDDPI
Study NCT01846013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand
Description: Stand at least half of the workday at work.
Study NCT00615459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18 μg once daily delivered via inhalation device
Study NCT00615459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
Study NCT00736593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon™ or Nexagon™ vehicle
Study NCT03148795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1 mg daily
Study NCT04399252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Participants will take 2 capsules per day of either LGG or placebo.
Study NCT04399252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus rhamnosus GG Placebo
Description: Participants will take 2 capsules per day of LGG placebo
Study NCT04306757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evone
Description: Airway ventilation device
Study NCT04306757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Primus
Description: Airway ventilation device
Study NCT00663104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercise: 3 joint sessions/week for 12 months
Study NCT00663104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise + cimicifuga racemosa
Description: exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
Study NCT00663104 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: wellness control, placebo
Description: 2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
Study NCT03986567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: gamification for partner notification among youngsters
Description: Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification
Study NCT03986567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gamification for partner notification among youngsters
Description: Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification
Study NCT00468611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBP8298
Description: 500mg MBP8298 IV every six months for a period of two years
Study NCT00468611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MBP8298
Description: 500mg MBP8298 IV every six months for a period of two years
Study NCT02746445 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
Study NCT01917552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 1250 milligram (mg) / m² po bid (D1-14)
Study NCT02017704 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Endo-HDR (if randomized to this arm)
Description: Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
Study NCT02017704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine and IMRT (if randomized to this arm)
Description: Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
Study NCT02017704 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT (intensity modulated radiation therapy)
Description: Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
Study NCT01846013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move
Description: Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
Study NCT01846013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand and Move
Description: Increase standing time to half of workday (4h) and increase movement time at work.
Study NCT00699374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
Study NCT00699374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
Study NCT02065700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Administered as Oral Tablets
Study NCT00859586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi Magnetic cell sorter for CD3
Description: Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
Study NCT00678197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access Intervention
Study NCT00678197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bonus/Pay-for-Performance Intervention
Study NCT02747550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LM with TESTO
Description: In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
Study NCT02747550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LM without TESTO
Description: In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
Study NCT01480843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
Study NCT02969681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: 1.5g/kg/day, D1-3, every 2 weeks
Study NCT02969681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: * mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks
Study NCT02969681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: * mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks
Study NCT04425135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg,D1,ivgtt, Q3w.
Study NCT04425135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg,Qd,Q3W.
Study NCT04425135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrixed
Description: 500 mg/m2,D1,ivgtt, Q3w.
Study NCT04425135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5\~6,D1,ivgtt, Q3w.
Study NCT00973609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
Description: Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): No maintenance treatment.
Study NCT00973609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
Description: Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab.
Study NCT00973609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
Description: Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy.
Study NCT04248218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Rehabilitation Group/Case
Description: If the patient is in the active rehabilitation group, the patient will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. In addition, they will also watch a two-minute video by the PI and research team reinforcing the active rehabilitation instructions.
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNR
Description: Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
Study NCT02017704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: * Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion.
Study NCT02017704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX6
Description: * Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion.
Study NCT02017704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis.
Study NCT02017704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis.